summary Backgrounds Cancer patients presented a lower probability to obtain seroconversion after a complete course of COVID-19 vaccination. However, little was known on the factors that predict poor seroconversion in this frail population. Methods We searched the PubMed, EMBASE and CNKI (China National Knowledge Infrastructure) databases for all articles within a range of published years from 2019 to 2022 on the predictors of response to COVID 19 vaccine in cancer patients (last search was update 2st March, 2022). The odds ratio (OR) corresponding to the 95% confidence interval (95% CI) was used to assess the outcome. The statistical heterogeneity among studies was assessed with the Q-test and I2 statistics. The review was registered with PROSPERO (CRD42022315687) and reported according to PRISMA guidelines. Results 20 cohort studies met the inclusion criteria for this study, with 5,499 cancer patients. We found that advanced age, male patients, and metastatic disease increased negative seropositivity to COVID19 vaccine. IGHV mutation status, high concentration of Ig G, Ig M and Ig A were correlated with seropositivity. Relating to cancer treatment strategy, anti-CD20 therapy within recent 12 months and chemotherapy were negatively correlated with seroconversion. Meta-analysis found no significant difference associated with targeted treatment, immunotherapy, and endocrine treatment. Conclusions Our meta-analysis assessed the factors that predict poor seroconversion in order to plan better prevention strategies in this frail population. The results proposed that enhanced vaccination strategies would be beneficial for the special patients such as advanced male, or patients receiving active chemotherapy, and carefully prevention should be emphasized even after a complete course of vaccination.
- All age groups
- Vaccine/vaccination
- COVID-19
- Efficacy/effectiveness
